※ PTMD 2.0 database Online Browse Options
Browse result for Lymphoma
※ introduction Lymphoma is a group of blood and lymph tumors that develop from lymphocytes (a type of white blood cell). The name typically refers to just the cancerous versions rather than all such tumours. Signs and symptoms may include enlarged lymph nodes, fever, drenching sweats, unintended weight loss, itching, and constantly feeling tired. The enlarged lymph nodes are usually painless. The sweats are most common at night.
Many subtypes of lymphomas are known. The two main categories of lymphomas are the non-Hodgkin lymphoma (NHL) (90% of cases) and Hodgkin lymphoma (HL) (10%). Lymphomas, leukemias and myelomas are a part of the broader group of tumors of the hematopoietic and lymphoid tissues.
Risk factors for Hodgkin lymphoma include infection with Epstein¨CBarr virus and a history of the disease in the family. Risk factors for common types of non-Hodgkin lymphomas include autoimmune diseases, HIV/AIDS, infection with human T-lymphotropic virus, immunosuppressant medications, and some pesticides. In 2014, the International Agency for Research on Cancer updated its classification of trichloroethylene to Group 1, indicating that sufficient evidence exists that it causes cancer of the kidney in humans as well as some evidence of cancer of the liver and non-Hodgkin's lymphoma. Eating large amounts of red meat and tobacco smoking may also increase the risk. Diagnosis, if enlarged lymph nodes are present, is usually by lymph node biopsy. Blood, urine, and bone marrow testing may also be useful in the diagnosis. Medical imaging may then be done to determine if and where the cancer has spread. Lymphoma most often spreads to the lungs, liver, and brain.
Treatment may involve one or more of the following: chemotherapy, radiation therapy, proton therapy, targeted therapy, and surgery. In some non-Hodgkin lymphomas, an increased amount of protein produced by the lymphoma cells causes the blood to become so thick that plasmapheresis is performed to remove the protein. Watchful waiting may be appropriate for certain types. The outcome depends on the subtype with some being curable and treatment prolonging survival in most. The five-year survival rate in the United States for all Hodgkin lymphoma subtypes is 85%, while that for non-Hodgkin lymphomas is 69%. Worldwide, lymphomas developed in 566,000 people in 2012 and caused 305,000 deaths. They make up 3¨C4% of all cancers, making them as a group the seventh-most common form. In children, they are the third-most common cancer. They occur more often in the developed world than the developing world.
Reference
Wiki: Lymphoma
Reference
Wiki: Lymphoma
| PTMD ID | UniProt Accession | Entrez ID | Gene Name | Protein Name | Organism |
|---|---|---|---|---|---|
| PTMD00592 | P41182 | 604 | BCL6 | B-cell lymphoma 6 protein | Homo sapiens |
| PTMD00333 | Q15717 | 1994 | ELAVL1 | ELAV-like protein 1 | Homo sapiens |
| PTMD00863 | P02452 | 1277 | COL1A1 | Collagen alpha-1 chain | Homo sapiens |
| PTMD00144 | Q12933 | 7186 | TRAF2 | TNF receptor-associated factor 2 | Homo sapiens |
| PTMD00955 | O95999 | 8915 | BCL10 | B-cell lymphoma/leukemia 10 | Homo sapiens |
| PTMD00945 | Q16539 | 1432 | MAPK14 | Mitogen-activated protein kinase 14 | Homo sapiens |
| PTMD00065 | P28482 | 5594 | MAPK1 | Mitogen-activated protein kinase 1 | Homo sapiens |
| PTMD00058 | P27361 | 5595 | MAPK3 | Mitogen-activated protein kinase 3 | Homo sapiens |
| PTMD00031 | P46527 | 1027 | CDKN1B | Cyclin-dependent kinase inhibitor 1B | Homo sapiens |
| PTMD00179 | P46531 | 4851 | NOTCH1 | Neurogenic locus notch homolog protein 1 [Cleaved into: Notch 1 extracellular truncation ; Notch 1 intracellular domain ] | Homo sapiens |
| PTMD00224 | P62805 | 12150 | H4C1 | Histone H4 | Homo sapiens |
| PTMD00213 | P42224 | 6772 | STAT1 | Signal transducer and activator of transcription 1-alpha/beta | Homo sapiens |
| PTMD00957 | O15524 | 8651 | SOCS1 | Suppressor of cytokine signaling 1 | Homo sapiens |
| PTMD00019 | P04150 | 2908 | NR3C1 | Glucocorticoid receptor | Homo sapiens |
| PTMD00006 | P04637 | 7157 | TP53 | Cellular tumor antigen p53 | Homo sapiens |
| PTMD00202 | P08581 | 4233 | MET | Hepatocyte growth factor receptor | Homo sapiens |
| PTMD00040 | P40763 | 6774 | STAT3 | Signal transducer and activator of transcription 3 | Homo sapiens |
| PTMD00906 | P42226 | 6778 | STAT6 | Signal transducer and activator of transcription 6 | Homo sapiens |
| PTMD00941 | P42229 | 6776 | STAT5A | Signal transducer and activator of transcription 5A | Homo sapiens |
| PTMD00041 | P49841 | 2932 | GSK3B | Glycogen synthase kinase-3 beta | Homo sapiens |
| PTMD00660 | Q06124 | 5781 | PTPN11 | Tyrosine-protein phosphatase non-receptor type 11 | Homo sapiens |
| PTMD00231 | Q13616 | 8454 | CUL1 | Cullin-1 | Homo sapiens |
| PTMD01360 | P15529 | 4179 | CD46 | Membrane cofactor protein | Homo sapiens |
| PTMD01101 | P51692 | 6777 | STAT5B | Signal transducer and activator of transcription 5B | Homo sapiens |
| PTMD01673 | P56537 | 3692 | EIF6 | Eukaryotic translation initiation factor 6 GCN homolog) ) | Homo sapiens |
| PTMD00928 | Q80YR6 | 22518 | Rbbp8 | DNA endonuclease RBBP8 | Mus musculus |
| PTMD00499 | P02340 | 22059 | Tp53 | Cellular tumor antigen p53 | Mus musculus |
| PTMD01347 | P22682 | 12402 | Cbl | E3 ubiquitin-protein ligase CBL | Mus musculus |
